Author Archives: Guest Blogger

Pharma in Argentina: An Interview with Juan Pablo Bagó

2014 marked the 80th anniversary of Laboratorios Bagó, a market leader in Argentina and also  Latin America, with products in  in 47 countries. In this interview with Pharmaboardroom.com, Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover […]
Posted in Emerging Markets, Global, R&D, Strategy | Tagged , , , , | Leave a comment

What’s All This Talk About Patient Centricity?

For Moe Alsumidaie, the most concrete definition for patient centricity is “a dynamic process through which the patient regulates the flow of information to and from him/her via multiple pathways to exercise choice that is consistent with his/her preferences, values and beliefs. This fundamentally transformative concept affects how healthcare decisions are made and who has […]
Posted in Guest Blog | Tagged , , | Leave a comment

Pharma and Biotech Trends 2014

Peter Young examines the fast-moving growth drivers for the two segments and what their 2014 numbers mean for respective M&A and other strategies going forward. The pharmaceutical and biotechnology industries, like all industries, are facing industry-specific changes coupled with disruptive events in the external global environment. The industry business factors include the productivity and cost […]
Posted in Biotech, Deals, Guest Blog, Op-Ed, Strategy | Tagged , , , , , | Leave a comment

UK: Saatchi Innovation Bill Still Divisive

 The innovation debate (Why isn’t there more or it? How much should we pay for it? Just what is it anyway?!) remains a lively one in the UK. Lord Saatchi’s Medical Innovation Bill is just one part of this debate. It’s intended to mitigate against so called ‘defensive’ medicine, where clinicians might not prescribe or […]
Posted in Europe, Guest Blog | Tagged , , , , | 4 Comments

Risking It All? Risk-Based Monitoring at Cancer Research UK

“Only those who risk going too far can possibly find out how far they can go,” said T.S. Elliot. Cancer Research UK (CRUK) followed this advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials. This decision has revealed how risk-adjusted approaches […]
Posted in R&D, Strategy | Tagged , , , , | Leave a comment
  • Categories

  • Meta